IndraLab

Statements

TNFAIP3 activates Receptors, Antigen, B-Cell. 3 / 3
| 3
reach
"TNFAIP3, as a distal member of the BCR signaling pathway, may be expected to restore BCR pathway activity in the presence of ibrutinib, and its mutation status is often associated with poor efficacy of ibrutinib monotherapy (31)."
39913173
reach
"83 In ABC DLBCL, biallelic inactivation of TNFAIP3 (by mutations, deletions or both) occurs in 30% of cases and can coexist with mutations in both MYD88 and CD79B, suggesting that inactivation of TNFAIP3 can enhance both BCR and TLR signalling pathways."
24217204
reach
"The fact that patients with N1 tumors benefitted exceptionally from ibrutinib suggests that the recurrent mutations in PRKCB, BCL10, IKBKB, TNFAIP3 and TNIP1 in these tumors might also potentiate chronic active BCR signaling and reinforce BTK dependency."
34739844